EGFR and non-small cell lung carcinoma: These findings suggested that circulating DNA can act as a potential diagnostic marker for NSCLC.27 Epidermal growth factor receptor (EGFR) mutation status is an important biomarker for NSCLC targeted therapy so it is helpful to have an early diagnosis about mutation type for getting optimal targeted therapy.